On November 5, Hyperliquid generated a record $521,000 in priority fees, which accounted for 12.7% of the platform's daily revenue. This spike occurred during a sharp selloff in U.S. stocks, driving traders like liquidation bots and arbitrageurs to pay extra fees for faster transaction processing. Priority fees are additional payments made to prioritize transactions when network congestion is high. The record highlights increased competition for transaction speed during market turmoil, signaling heightened activity and demand on the platform.
Hyperliquid's record $521,000 in daily priority fees during a U.S. stock selloff signals intense competition for transaction speed. For readers following the cryptocurrency market, here is Pluang's market snapshot as of Nov 06, 2026 07:02 WIB: out of 50 major cryptocurrencies, 3 rose and 46 fell. Notable movers include UNI at Rp123.887 with a 10.85% drop and an 83% sell order activity, ZIL at Rp30 down 10.26% with 82% buy orders, and SNX at Rp2.944 down 10.08% with balanced order activity.
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Stacks (STX) surged 9.99% to $0.360, leading gains among the 90 largest cryptocurrencies as 77 advanced over 24 hours. Other notable winners included Injective (INJ) up 9.37%, Pearl (PEARL) up 8.29%, Render (RENDER) up 7.26%, and PancakeSwap (CAKE) u...
Perspective Therapeutics presented new Phase 1/2a trial data showing that bamzireotide (VMT-α-NET) achieved durable disease control and promising tumor responses in patients with advanced neuroendocrine tumors expressing SSTR2. Among 57 patients with...
